A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer (Q60362076)
Jump to navigation
Jump to search
scientific article published on 14 February 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer |
scientific article published on 14 February 2011 |
Statements
A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer (English)
G R Blumenschein
F Kabbinavar
H Menon
T S K Mok
J Stephenson
J T Beck
K Lakshmaiah
K Reckamp
Y-J Hei
K Kracht
Y-N Sun
R Sikorski
L Schwartzberg
Motesanib NSCLC Phase II Study Investigators
14 February 2011